Thomas F. Isett
Chief Executive Officer at Transposagen Biopharmaceuticals, Inc.
Net worth: 2 436 $ as of 2024-03-30
Profile
Thomas F.
Isett is currently the Chief Executive Officer at Transposagen Biopharmaceuticals, Inc. and Chairman & Chief Executive Officer at iBio CDMO LLC.
Previously, he was the Chief Executive Officer & Director at iBio, Inc. from 2019 to 2022.
He also served as the Chief Executive Officer at Commence Biologics, Inc., Managing Director at i.e.
Advising LLC, Vice President-Advanced Bioprocessing at Becton, Dickinson & Co., and General Manager-BioProcess at General Electric Co. Additionally, he was the Head-Cell Processing Technologies at Lonza AG from 2009 to 2012.
He received his undergraduate degree from Drexel University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
IBIO, INC.
0.01% | 2023-10-24 | 600 ( 0.01% ) | 2 436 $ | 2024-03-30 |
Thomas F. Isett active positions
Companies | Position | Start |
---|---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Chief Executive Officer | 2017-07-31 |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a private company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Chief Executive Officer | - |
Former positions of Thomas F. Isett
Companies | Position | End |
---|---|---|
IBIO, INC. | Chief Executive Officer | 2022-11-30 |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Corporate Officer/Principal | 2011-12-31 |
BECTON, DICKINSON AND COMPANY | Corporate Officer/Principal | 2008-12-31 |
Commence Biologics, Inc. | Chief Executive Officer | - |
i.e. Advising LLC | Chief Executive Officer | - |
Training of Thomas F. Isett
Drexel University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
BECTON, DICKINSON AND COMPANY | Health Technology |
GE AEROSPACE | Producer Manufacturing |
IBIO, INC. | Health Technology |
Private companies | 5 |
---|---|
Transposagen Biopharmaceuticals, Inc.
Transposagen Biopharmaceuticals, Inc. BiotechnologyHealth Technology Transposagen Biopharmaceuticals, Inc. operates as a biotechnology company. Its products and services include piggyBac Reagents, cell engineering services and gene editing reagents & kits. The company was founded by Ostertag M. Eric in 2005 and is headquartered in Lexington, KY. | Health Technology |
Lonza AG
Lonza AG BiotechnologyHealth Technology Lonza AG engages in the research in as well as development, production, and distribution of chemical products and materials. The firm also carries out investment and lending transactions. The company was founded on December 7, 1897 and is headquartered in Visp, Switzerland. | Health Technology |
iBio CDMO LLC
iBio CDMO LLC BiotechnologyHealth Technology Part of iBio, Inc., iBio CDMO LLC is a private company that is advancing its immuno-oncology pipeline of antibody therapeutic candidates against hard-to-drug tumor targets. The company is based in Bryan, TX. The company uses its patented discovery platform, which leverages artificial intelligence to consistently deliver antibody candidates against difficult targets. The company's lead candidate, IBIO-101, stimulates anti-tumor immunity by selectively depleting immunosuppressive TREG cells while sparing tumor cell killing T-Effector cells. iBio is pioneering the next generation of antibody therapeutics, leveraging its artificial intelligence-based and epitope steered antibody discovery platform. The company seeks to partner IBIO-400 to develop a safe and effective subunit vaccine capable of differentiating infected from vaccinated animals. The CEO of the company is Thomas F. Isett. | Health Technology |
i.e. Advising LLC | |
Commence Biologics, Inc. |
- Stock Market
- Insiders
- Thomas F. Isett